

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Alison Helena Goodall et al.
Application No. : 10/574,872
Int'l Filing Date : October 7, 2004
For : FIBRINOGEN TARGETTING MICROPARTICLES FOR
PROMOTING HAEMOSTASIS

Docket No. : 430160.401USPC
Date : November 28, 2006

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:


In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Information Disclosure Statement. Copies of cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of any other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

A handwritten signature in black ink, appearing to read "Stephen J. Rosenman", is written over a horizontal line.

Stephen J. Rosenman, Ph.D.

Registration No. 43,058

SJR:rp

Enclosures:

Information Disclosure Statement
Cited References (27)

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031

870535_1.DOC

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. 430160.401USPC		APPLICATION NO. 10/574,872	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Alison Helena Goodall			
				INT'L FILING DATE October 7, 2004		GROUP ART UNIT	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AA	2003/0021777	01/30/03	Harris et al.	424	94.64		

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
				YES	NO	
AA	WO9817319	04/30/98	PCT			
AB	WO9925383	05/27/99	PCT			
AC	WO9942146	08/26/99	PCT			
AD	WO0029028	05/25/00	PCT			
AE	WO04045542	6/03/04	PCT			
AF	WO04069862	08/19/04	PCT		X	
AG	EP0618225	10/05/94	EP (+English Abstract)			

OTHER PRIOR ART <small>(Including Author, Title, Date, Pertinent Pages, Etc.)</small>		
AH		Agam G., et al. "Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia," <i>Eur. J. Clin. Invest.</i> , 22(2):105-112, February 1992.
AI		Beer, J.H., "Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor," <i>Blood</i> , 79(1):117-128, January 1, 1992.
AJ		Bennett, Joel S., "Platelet-Fibrinogen Interactions," <i>Annals of the New York Academy of Sciences</i> , 936:340-354, 2001.
AK		Blajchman, M. A., et al. "Substitutes and alternatives to platelet transfusions in thrombocytopenic patients," <i>Journal of Thrombosis and Haemostasis</i> , 1:1637-1641, July 2003.
AL		Charo et al., "Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide," <i>J. Biol. Chem.</i> , 266(3):1415-1421, January 1991.
AM		Coller et al., "Thromboerythrocytes In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions," <i>J. Clin. Invest.</i> , 89(2):546-555, February 1992.
AN		Davies A.R., "Effects of Synthocytes TM , A Novel Platelet Substitute, on Platelet Function," Congress XVII ISTH, 1999.
AO		Davies, A.R. et al., "Interactions of platelets with Synthocytes TM , a novel platelet substitute," <i>Platelets</i> , 13(4):197-205, June 2002.

EXAMINER	DATE CONSIDERED
----------	-----------------

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY. DOCKET NO.	APPLICATION NO.
		430160.401USPC	10/574,872
		APPLICANTS	
		Alison Helena Goodall	
		INT'L FILING DATE	GROUP ART UNIT
		October 7, 2004	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BA	Derrick, et al., "Peptide LSARLAF activates $\alpha_{IIb}\beta_3$ on resting platelets and causes resting platelet aggregate formation without platelet shape change," <i>Thromb Res.</i> , 89(1):31-40, January 1, 1998.	
	BB	Doolittle, "Fibrinogen and Fibrin," Haemostasis and Thromboses, p.491-513, 1994.	
	BC	D'Souza et al., "A discrete sequence in a platelet integrin is involved in ligand recognition," <i>Nature</i> , 350:66 - 68, March 7 1991.	
	BD	D'Souza et al., "The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its α subunit," <i>J. Biol. Chem.</i> , 265(6): 3440-3446, February 1990.	
	BE	Grunkemeier, J.M., et al. "Fibrinogen adsorption to receptor-like biomaterials made by pre-adsorbing peptides to polystyrene substrates," <i>Journal of Molecular Recognition</i> , 9(3):247-257, 1996.	
	BF	Kuyas C., et al., "Isolation of human fibrinogen and its derivatives by affinity chromatography on Gly-Pro-Arg-Pro-Lys-Fractogel," <i>Thrombosis and Haemostasis</i> , 63(3):439-444, June 28, 1990.	
	BG	Levi, M. et al., "Fibrogen-Coated Albumin Microcapsules Reduce Bleeding in Severely Thrombocytopenic Rabbits," <i>Nature Medicine</i> , 5(1):107-111, January 1999.	
	BH	Moskowitz et al., "Fibrinogen coating density affects the conformation of immobilized fibrinogen: implications for platelet adhesion and spreading," <i>Thromb Haemost.</i> , 79(4):824-830, 1998.	
	BI	Perkins et al., "Human biodistribution of an ultrasound contrast agent (Quantison TM) by radiolabelling and gamma scintigraphy," <i>The British Journal of Radiology</i> , 70(834):603-611, 1997.	
	BJ	Steiner et al., "Peptides derived from a sequence within β_3 integrin bind to platelet $\alpha_{IIb}\beta_3$ (GPIIb-IIIa) and inhibit ligand binding," <i>J. Biol. Chem.</i> , 268(10): 6870-6873, April 5, 1993.	
	BK	Taylor et al., "A peptide corresponding to GPIIb α 300-312, a presumptive fibrinogen γ chain binding site on the platelet integrin GPIIb/IIIa, inhibits the adhesion of platelets to at least four adhesive ligands," <i>J. Biol. Chem.</i> , 267(17):11729-11733, June 1992.	
	BL	Ware et al., "Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization," <i>Protein Science</i> , 8(12):2663-2671, 1999.	
EXAMINER		DATE CONSIDERED	